Clinical trial
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
NCT03629379 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 22, 2019
- Completion date
- July 1, 2021
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.